These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16954719)

  • 21. "Nothing new": responses to the introduction of antiretroviral drugs in South Africa.
    Chopra M; Kendall C; Hill Z; Schaay N; Nkonki LL; Doherty TM
    AIDS; 2006 Oct; 20(15):1975-7. PubMed ID: 16988520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?
    Battegay M; Bucher HC
    AIDS; 2010 Apr; 24(7):1057-9. PubMed ID: 20032771
    [No Abstract]   [Full Text] [Related]  

  • 23. The challenge of assuring continued post-trial access to beneficial treatment.
    Grady C
    Yale J Health Policy Law Ethics; 2005; 5(1):425-35. PubMed ID: 15742586
    [No Abstract]   [Full Text] [Related]  

  • 24. HIV priorities and health distributions in a rural region in Tanzania: a qualitative study.
    Johansson KA; Miljeteig I; Kigwangalla H; Norheim OF
    J Med Ethics; 2011 Apr; 37(4):221-6. PubMed ID: 21262784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The long-term consequences of antiretroviral therapy.
    Smith D
    J HIV Ther; 2006 Jun; 11(2):24-5. PubMed ID: 16981592
    [No Abstract]   [Full Text] [Related]  

  • 26. Freebies for subject 641: a discussion of the ethical prospect of providing drug trial subjects with post-trial access to the drug tested--a Canadian perspective.
    Hutt LE
    Health Law J; 1998; 6 Spec No():169-87. PubMed ID: 14746066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barriers to access to antiretroviral treatment in developing countries: a review.
    Posse M; Meheus F; van Asten H; van der Ven A; Baltussen R
    Trop Med Int Health; 2008 Jul; 13(7):904-13. PubMed ID: 18466183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orphanhood predicts delayed access to care in Ugandan children.
    Ntanda H; Olupot-Olupot P; Mugyenyi P; Kityo C; Lowes R; Cooper C; Lima V; Mills E
    Pediatr Infect Dis J; 2009 Feb; 28(2):153-5. PubMed ID: 19131904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long-term consequences of antiretroviral therapy: a review.
    Boyd M; Reiss P
    J HIV Ther; 2006 Jun; 11(2):26-35. PubMed ID: 16981593
    [No Abstract]   [Full Text] [Related]  

  • 30. Moving toward assured access to treatment in microbicide trials. Global Campaign for Microbicides.
    Forbes A
    PLoS Med; 2006 Jul; 3(7):e153. PubMed ID: 16805648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV vaccine trials: reconsidering the therapeutic misconception and the question of what constitutes trial related injuries.
    Schüklenk U; Ashcroft R
    Dev World Bioeth; 2007 Dec; 7(3):ii-iv. PubMed ID: 18021115
    [No Abstract]   [Full Text] [Related]  

  • 32. Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries.
    Souteyrand YP; Collard V; Moatti JP; Grubb I; Guerma T
    AIDS; 2008 Jul; 22 Suppl 1():S161-8. PubMed ID: 18664948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reconsidering the impact of conflict on HIV infection among women in the era of antiretroviral treatment scale-up in sub-Saharan Africa: a gender lens.
    Shannon K; Kaida A; Rachlis B; Lloyd-Smith E; Gray G; Strathdee SA
    AIDS; 2008 Sep; 22(14):1705-7. PubMed ID: 18753938
    [No Abstract]   [Full Text] [Related]  

  • 34. COMMENTARY: understanding the benefits of pediatric anti-retroviral treatment in resource-limited settings.
    Hetherington S
    Pediatr Infect Dis J; 2009 Jan; 28(1):41-2. PubMed ID: 19057455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should post-trial provision of beneficial experimental interventions be mandatory in developing countries?
    Zong Z
    J Med Ethics; 2008 Mar; 34(3):188-92. PubMed ID: 18316461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV testing strategies across European countries.
    Mounier-Jack S; Nielsen S; Coker RJ
    HIV Med; 2008 Jul; 9 Suppl 2():13-9. PubMed ID: 18557864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nearly three million HIV-positive people now receiving life-saving drugs. But access to prevention and treatment still lacking for millions.
    Cent Eur J Public Health; 2008 Sep; 16(3):127, 133. PubMed ID: 18935778
    [No Abstract]   [Full Text] [Related]  

  • 38. The marriage of science and optimized HIV care in resource-limited settings.
    Calmy A; Pizzocolo C; Pizarro L; Brücker G; Murphy R; Katlama C;
    AIDS; 2008 Nov; 22(17):2227-30. PubMed ID: 18981761
    [No Abstract]   [Full Text] [Related]  

  • 39. Evidence-based prevention: increasing the efficiency of HIV intervention trials.
    Padian NS
    J Infect Dis; 2004 Aug; 190(4):663-5. PubMed ID: 15272391
    [No Abstract]   [Full Text] [Related]  

  • 40. A national survey of prisoners on antiretroviral therapy in Malawi: access to treatment and outcomes on therapy.
    Makombe SD; Jahn A; Tweya H; Thambo L; Yu JK; Hedt B; Weigel R; Nkhata A; Schouten EJ; Kamoto K; Harries AD
    J Infect Dev Ctries; 2007 Dec; 1(3):303-7. PubMed ID: 19734609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.